These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 10897039)

  • 21. Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
    Brouwenstijn N; Gaugler B; Krüse KM; van der Spek CW; Mulder A; Osanto S; van den Eynde BJ; Schrier PI
    Int J Cancer; 1996 Oct; 68(2):177-82. PubMed ID: 8900424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of an HLA-A2-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2).
    Yoshimura S; Tsunoda T; Osawa R; Harada M; Watanabe T; Hikichi T; Katsuda M; Miyazawa M; Tani M; Iwahashi M; Takeda K; Katagiri T; Nakamura Y; Yamaue H
    PLoS One; 2014; 9(1):e85267. PubMed ID: 24416375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
    Fisk B; Blevins TL; Wharton JT; Ioannides CG
    J Exp Med; 1995 Jun; 181(6):2109-17. PubMed ID: 7539040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine.
    Shawler DL; Bartholomew RM; Garrett MA; Trauger RJ; Dorigo O; Van Beveren C; Marchese A; Ferre F; Duffy C; Carlo DJ; Sherman LA; Gold DP; Sobol RE
    Clin Exp Immunol; 2002 Jul; 129(1):99-106. PubMed ID: 12100028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.
    Yoshino I; Goedegebuure PS; Peoples GE; Parikh AS; DiMaio JM; Lyerly HK; Gazdar AF; Eberlein TJ
    Cancer Res; 1994 Jul; 54(13):3387-90. PubMed ID: 7912166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.
    Goedegebuure PS; Douville CC; Doherty JM; Linehan DC; Lee KY; Ganguly EK; Eberlein TJ
    Cell Immunol; 1997 Feb; 175(2):150-6. PubMed ID: 9023420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes.
    Kono K; Rongcun Y; Charo J; Ichihara F; Celis E; Sette A; Appella E; Sekikawa T; Matsumoto Y; Kiessling R
    Int J Cancer; 1998 Oct; 78(2):202-8. PubMed ID: 9754653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient.
    Verdegaal EM; Huinink DB; Hoogstraten C; Marijnissen AK; Gorsira MB; Claas FH; Osanto S
    Hum Immunol; 1999 Dec; 60(12):1195-206. PubMed ID: 10626733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
    Yoshino I; Peoples GE; Goedegebuure PS; Maziarz R; Eberlein TJ
    J Immunol; 1994 Mar; 152(5):2393-400. PubMed ID: 8133050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones.
    Perez SA; Sotiropoulou PA; Sotiriadou NN; Mamalaki A; Gritzapis AD; Echner H; Voelter W; Pawelec G; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2002 Jan; 50(11):615-24. PubMed ID: 11807625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line.
    Santegoets SJ; Schreurs MW; Masterson AJ; Liu YP; Goletz S; Baumeister H; Kueter EW; Lougheed SM; van den Eertwegh AJ; Scheper RJ; Hooijberg E; de Gruijl TD
    Cancer Immunol Immunother; 2006 Dec; 55(12):1480-90. PubMed ID: 16468034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Her-2/ neu altered peptide ligand-induced CTL responses: implications for peptides with increased HLA affinity and T-cell-receptor interaction.
    Dionne SO; Myers CE; Smith MH; Lake DF
    Cancer Immunol Immunother; 2004 Apr; 53(4):307-14. PubMed ID: 14605764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
    Zaks TZ; Rosenberg SA
    Cancer Res; 1998 Nov; 58(21):4902-8. PubMed ID: 9809997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8.
    Lustgarten J; Theobald M; Labadie C; LaFace D; Peterson P; Disis ML; Cheever MA; Sherman LA
    Hum Immunol; 1997 Feb; 52(2):109-18. PubMed ID: 9077559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties.
    Gritzapis AD; Voutsas IF; Lekka E; Tsavaris N; Missitzis I; Sotiropoulou P; Perez S; Papamichail M; Baxevanis CN
    J Immunol; 2008 Jul; 181(1):146-54. PubMed ID: 18566379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
    Baxevanis CN; Gritzapis AD; Tsitsilonis OE; Katsoulas HL; Papamichail M
    Int J Cancer; 2002 Apr; 98(6):864-72. PubMed ID: 11948464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells.
    Kawashima I; Tsai V; Southwood S; Takesako K; Sette A; Celis E
    Cancer Res; 1999 Jan; 59(2):431-5. PubMed ID: 9927058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu.
    Peiper M; Goedegebuure PS; Izbicki JR; Eberlein TJ
    Anticancer Res; 1999; 19(4A):2471-5. PubMed ID: 10470176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.
    Vertuani S; Triulzi C; Roos AK; Charo J; Norell H; Lemonnier F; Pisa P; Seliger B; Kiessling R
    Cancer Immunol Immunother; 2009 May; 58(5):653-64. PubMed ID: 18820911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.
    Mimura K; Kono K; Southwood S; Fikes J; Takahashi A; Miyagawa N; Sugai H; Fujii H
    Cancer Immunol Immunother; 2006 Nov; 55(11):1358-66. PubMed ID: 16435129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.